- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03783884
Ein Protokoll zum Vergleich der temporären transvenösen Zwerchfellstimulation mit dem Behandlungsstandard für die Entwöhnung von der mechanischen Beatmung (RESCUE 3)
Eine randomisierte, kontrollierte, offene, multizentrische klinische Studie zur Bewertung der sicheren und effektiven Leistung des Lungpacer-Zwerchfellstimulationstherapiesystems bei Patienten, die sich nicht von der mechanischen Beatmung entwöhnen konnten.
This clinical investigation is an open-label, multi-center, randomized clinical trial (RCT) to demonstrate the safety and effective performance of the Lungpacer DPTS (plus standard of care) as compared to Control (standard of care only) in patients aged 18 years or older who are receiving mechanical ventilation. Eligible Subjects will have received mechanical ventilation for ≥96 hours (4 days) and have failed two weaning attempts.
The goal or outcome is to show a numerically greater proportion of subjects weaned in the Treatment (Lungpacer DPTS) group as compared to the Control group.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The intended patient population is applicable for Lungpacer Diaphragm Pacing Therapy (DPT) because there are no noninvasive alternative treatments for patients who are difficult to wean from MV (i.e., ≥96 hours (4 days) on MV) or who have required prolonged MV (>7 days). The intended patient population includes approximately one-third of all patients on mechanical ventilation. Under standard of care, approximately 50% of these patients will recover from mechanical ventilation (Jung, 2016). Standard of care involves daily weaning attempts, known as Spontaneous Breathing Trials (SBTs) or Ventilator Liberation Trials (VLTs) that are intended to encourage diaphragm use and strengthening over time.Therefore, Lungpacer DPT efficacy evaluation must be compared to standard of care in a Control group. Lack of recovery from mechanical ventilation may be due to the inability of a patient to participate in VLTs or weaning attempts, due to extensive diaphragm weakness or sedation, the inability of VLTs to induce sufficient diaphragm strengthening, or co-morbidities that prevent recovery.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Berlin, Deutschland, 10117
- Berlin Charite Mitte
-
Essen, Deutschland, 45276
- KEM Essen
-
Löwenstein, Deutschland, 74245
- SLK Löwenstein
-
Nuremberg, Deutschland, 90419
- Nürnberg Klinikum Nord
-
Schmallenberg, Deutschland, 57392
- FKKG Schmallenberg
-
Solingen, Deutschland, 42699
- Solingen Krankenhaus Bethanien
-
-
Mecklenburg-Vorpommern
-
Greifswald, Mecklenburg-Vorpommern, Deutschland, 17475
- Universitätsmedizin Greifswald
-
-
-
-
-
Angers, Frankreich, 49933
- CHU Angers
-
Montpellier, Frankreich, 34295
- CHU Montpellier
-
Paris, Frankreich, 75651
- Hôpital La Pitié-Salpêtrière
-
Strasbourg, Frankreich, 67091
- CHU Strasbourg
-
-
-
-
California
-
Stanford, California, Vereinigte Staaten, 94305
- Stanford University Medical Center
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- University of Colorado Anschutz Medical Campus
-
-
Florida
-
Gainesville, Florida, Vereinigte Staaten, 32610
- University of Florida, Shands
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60612
- Rush University Medical Center
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Northwestern University Feinberg School of Medicine
-
Chicago, Illinois, Vereinigte Staaten, 60612
- U of Illinois at Chicago
-
Hines, Illinois, Vereinigte Staaten, 60141
- Edward Hines VA Hospital
-
Maywood, Illinois, Vereinigte Staaten, 60153
- Loyola University Medical Center
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Indiana University Health Methodist Hospital
-
-
Kentucky
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- University of Louisville
-
-
Massachusetts
-
Burlington, Massachusetts, Vereinigte Staaten, 01805
- Lahey Hospital and Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55407
- Minneapolis Heart Institute Foundation
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68124
- CHI Health Creighton University Medical Center - Bergan Mercy
-
-
New Jersey
-
Englewood, New Jersey, Vereinigte Staaten, 07631
- Englewood Hospital Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45267
- University of Cincinnati
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Ohio State University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19140
- Temple University Hospital
-
-
Rhode Island
-
Warwick, Rhode Island, Vereinigte Staaten, 02886
- Kent County Memorial Hospital
-
-
South Carolina
-
Columbia, South Carolina, Vereinigte Staaten, 29203
- Prisma Health Baptist Hospital
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75390
- University of Texas Southwestern, Zale Lipshy Hospital
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84132
- University of Utah
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Are 18 years or older, and,
- Have been mechanically ventilated for ≥96 hours (4 days), and,
- Have satisfied the Readiness-to-Wean criteria, and,
- Have failed at least 2 weaning attempts (that were conducted at least 48 hours after initiation of MV, and, that were conducted on different calendar days, and, at least one of which was the protocol-specific Ventilator Liberation Trial).
Exclusion Criteria:
- Maximal Inspiratory Pressure (MIP) (absolute value) >50 cm H2O;
- Invasive mechanical ventilation >90 days;
- Currently on extracorporeal membrane oxygenation (ECMO);
- Weaning failure due to hypervolemia;
- Medical history (including imaging) or known anatomy that prevents percutaneous insertion of the Catheter into the intended thoracic vein on the left side.
- Clinically overt congestive heart failure that is preventing weaning;
- Currently being treated with neuromuscular blockade;
- Pre-existing neurological, neuromuscular or muscular disorder that could affect the respiratory muscles;
- Pre-existing severe chronic pulmonary fibrosis;
- Pleural effusions occupying greater than one third of the pleural space on either side;
- BMI >45 kg/m2;
- Known or suspected phrenic nerve paralysis;
- Any electrical device (implanted or external) that may be prone to interaction with, or interference from the Lungpacer DPTS including neurological pacing/stimulator devices, cardiac pacemakers and defibrillators;
- Current hemodynamic instability, sepsis or septic shock;
- Prior bacteremia reported within the last 48 hours;
- Anticipating withdrawal of life support and/or shift to palliation as the goal of care;
- Known or suspected to be pregnant or lactating;
- Currently being treated in another clinical trial studying an experimental treatment that could affect the study primary outcome.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Treatment
Subject receives Lungpacer Catheter for transvenous phrenic nerve stimulation to deliver Diaphragm Pacing Therapy Sessions. DPT sessions are 6 sets of 10, delivered twice daily, for a total of 120 stimulation reps per day, plus standard of care for weaning from mechanical ventilation. |
Transvenous phrenic nerve stimulation to induce diaphragm contraction.
Andere Namen:
|
|
Kein Eingriff: Control
Subject does not receive Lungpacer Catheter or DPT. Subject receives only Standard of care for weaning from mechanical ventilation. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Successful Weaning
Zeitfenster: Through Day 30
|
Cumulative percentage of subjects successfully weaned by Day 30. |
Through Day 30
|
|
Adverse Event Profile
Zeitfenster: 30 days
|
Characterize the adverse event profile to support an observed consistent risk profile for subjects randomized to Treatment compared to subjects randomized to Control. Percentage of subjects with adverse events (AE) and serious adverse events (SAE) were summarized for the Treatment group and the Control group by system organ class (SOC) and lower level term. No formal statistical hypothesis test or criterion for the primary safety endpoint was defined. |
30 days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Days on Mechanical Ventilation (MV)
Zeitfenster: Successful weaning or Day 30
|
The average days on mechanical ventilation from Day 1 to removal from MV associated with successful weaning or Day 30, whichever comes first, will be statistically significantly smaller for subjects randomized to Treatment as compared to subjects randomized to Control. |
Successful weaning or Day 30
|
|
Maximal Inspiratory Pressure (MIP) Change
Zeitfenster: Baseline last available measure through Day 30.
|
The mean improvement in inspiratory muscle strength as shown by the change in Maximal Inspiratory Pressure (MIP) from randomization to last available measure in subjects randomized to Treatment is superior to that in subjects randomized to Control. |
Baseline last available measure through Day 30.
|
|
Rapid Shallow Breathing Index (RSBI) Change
Zeitfenster: Baseline to last available measure through Day 30.
|
To determine change in Rapid Shallow Breathing Index (RSBI) from randomization to last available measure in subjects randomized to Treatment as compared to Control. RSBI measures the ratio of the respiratory rate to Tidal Volume in breaths/min/L and is commonly used as an index for weaning success. A reduction in RSBI is considered as clinical improvement. |
Baseline to last available measure through Day 30.
|
|
Survival
Zeitfenster: 30 days
|
Cumulative percentage of subjects who survived through Day 30. |
30 days
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Re-instatements of MV (After Successful Weaning) Through Day 30.
Zeitfenster: Through Day 30.
|
Assessment of re-instatements of MV in subjects who were successful weaned through Day 30 in the Treatment group as compared to the Control group. |
Through Day 30.
|
|
Tracheotomy After Randomization
Zeitfenster: Through 30 days
|
Assessment of percentage of subjects after randomization to Day 30 that required tracheostomy in the Treatment group as compared to the Control group. |
Through 30 days
|
|
ICU Discharges to Day 30.
Zeitfenster: through 30 days
|
Assessment of ICU discharges to Day 30 in the Treatment group as compared to the Control group. |
through 30 days
|
|
Hospital Discharges to Day 30.
Zeitfenster: through 30 days
|
Assessment of hospital admissions and discharges to Day 30 in the Treatment group as compared to the Control group. |
through 30 days
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- P-300
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Only investigators participating in this clinical trial will be able to see final de-identified participant data at the completion of the study.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .